Pediatric psychotropic prescribing and polypharmacy, 2019-2022: a retrospective electronic health record study in Qatar
- 1Pharmaceutical Sciences Department, College of Pharmacy, QU Health, Qatar University
- 2Department of Psychiatry, Hamad Medical Corporation
Abstract
Background: Real-world evidence on pediatric psychotropic prescribing and polypharmacy in Gulf health systems remains limited. Characterizing medication-class patterns and multi-class prescribing is essential for medication safety surveillance in children and adolescents. This study examined psychotropic prescribing, potential polypharmacy, and recorded medication combinations among children and adolescents using public-sector electronic health records in Qatar.
Methods: A retrospective observational study used electronic health record data from Hamad Medical Corporation and the Primary Health Care Corporation, Qatar’s principal public healthcare providers, from January 2019 to December 2022. Children and adolescents aged 0–17 years with at least one psychotropic prescription were included. Medications were classified as antidepressants, antipsychotics, anxiolytics, mood stabilizers, or attention-deficit/hyperactivity disorder (ADHD) medications. Potential cross-class polypharmacy was assessed as the recording of two or more medication classes per patient during the study period; available duration information did not permit confirmation of concurrent exposure. Logistic regression examined patient-level associations with this outcome.
Results: The dataset included 2,941 eligible prescription records corresponding to 2,221 unique patients. The proportion of prescriptions for ADHD medications decreased from 28.7% in 2019 to 13.7% in 2022, whereas the proportion assigned to anxiolytics increased from 26.0% to 37.5%. ADHD medications predominated among prescriptions for children aged 5–11 years, while antidepressants and antipsychotics predominated among those for adolescents aged 12–17 years. The potential-polypharmacy criterion was met by 322 patients (14.5%), reaching 21.6% among adolescents. In a gender-adjusted model restricted to patients aged 1–17 years, each additional year of age was associated with higher odds of meeting the criterion (adjusted OR 1.13, 95% CI 1.10-1.16). After excluding patients with prescription-linked seizure disorder or cerebral palsy, the corresponding proportion was 16.96% (259/1,527). Among patients meeting the criterion, antidepressant-antipsychotic and ADHD medication-antipsychotic pairs were most frequent; methylphenidate-risperidone was the most common recorded individual-drug pair.
Conclusions: This study characterizes pediatric psychotropic prescribing and potential polypharmacy in Qatar’s public healthcare records and helps address the limited regional evidence from Gulf health systems. The observed patterns identify potential medication-safety surveillance priorities, particularly among adolescents and patients with antipsychotic-containing medication histories. Further assessment incorporating exposure duration and clinical outcomes is needed to establish concurrency and clinical significance.
Related
- Psychotropic Drug Scheduling and Benzodiazepine Receptor Agonist Prescribing in Japan: An Interrupted Time Series Analysis
- Psychotropic prescribing trends in a Peruvian General Hospital during and after the COVID-19 pandemic: an interrupted time-series analysis
- Longitudinal changes in dose-normalized psychotropic medication exposure around transfer to a specialized older adult mental health service: a retrospective longitudinal study in Peru
- Patterns and appropriateness of antipsychotic prescribing in community-dwelling older adults: a retrospective study
- Clinical profiles, referral patterns and low vision aid prescribing across four rehabilitation centres in Ghana: protocol for a multicentre retrospective record review
BibTeX
@article{elella2026pediatric,
title = {{Pediatric psychotropic prescribing and polypharmacy, 2019-2022: a retrospective electronic health record study in Qatar}},
author = {Dina Moustafa Abo El-Ella and Dhoha Dhieb and Yousef Kanan and Sazgar Hamad and Kholoud Bastaki},
journal = {Frontiers in Psychiatry},
year = {2026},
month = oct,
doi = {10.3389/fpsyt.2026.1944247},
url = {https://www.frontiersin.org/articles/10.3389/fpsyt.2026.1944247/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Pediatric psychotropic prescribing and polypharmacy, 2019-2022: a retrospective electronic health record study in Qatar
AU - Dina Moustafa Abo El-Ella
AU - Dhoha Dhieb
AU - Yousef Kanan
AU - Sazgar Hamad
AU - Kholoud Bastaki
PY - 2026
DA - 2026/10/28
JO - Frontiers in Psychiatry
DO - 10.3389/fpsyt.2026.1944247
UR - https://www.frontiersin.org/articles/10.3389/fpsyt.2026.1944247/full
AB - Background: Real-world evidence on pediatric psychotropic prescribing and polypharmacy in Gulf health systems remains limited. Characterizing medication-class patterns and multi-class prescribing is essential for medication safety surveillance in children and adolescents. This study examined psychotropic prescribing, potential polypharmacy, and recorded medication combinations among children and adolescents using public-sector electronic health records in Qatar. Methods: A retrospective observational study used electronic health record data from Hamad Medical Corporation and the Primary Health Care Corporation, Qatar’s principal public healthcare providers, from January 2019 to December 2022. Children and adolescents aged 0–17 years with at least one psychotropic prescription were included. Medications were classified as antidepressants, antipsychotics, anxiolytics, mood stabilizers, or attention-deficit/hyperactivity disorder (ADHD) medications. Potential cross-class polypharmacy was assessed as the recording of two or more medication classes per patient during the study period; available duration information did not permit confirmation of concurrent exposure. Logistic regression examined patient-level associations with this outcome. Results: The dataset included 2,941 eligible prescription records corresponding to 2,221 unique patients. The proportion of prescriptions for ADHD medications decreased from 28.7% in 2019 to 13.7% in 2022, whereas the proportion assigned to anxiolytics increased from 26.0% to 37.5%. ADHD medications predominated among prescriptions for children aged 5–11 years, while antidepressants and antipsychotics predominated among those for adolescents aged 12–17 years. The potential-polypharmacy criterion was met by 322 patients (14.5%), reaching 21.6% among adolescents. In a gender-adjusted model restricted to patients aged 1–17 years, each additional year of age was associated with higher odds of meeting the criterion (adjusted OR 1.13, 95% CI 1.10-1.16). After excluding patients with prescription-linked seizure disorder or cerebral palsy, the corresponding proportion was 16.96% (259/1,527). Among patients meeting the criterion, antidepressant-antipsychotic and ADHD medication-antipsychotic pairs were most frequent; methylphenidate-risperidone was the most common recorded individual-drug pair. Conclusions: This study characterizes pediatric psychotropic prescribing and potential polypharmacy in Qatar’s public healthcare records and helps address the limited regional evidence from Gulf health systems. The observed patterns identify potential medication-safety surveillance priorities, particularly among adolescents and patients with antipsychotic-containing medication histories. Further assessment incorporating exposure duration and clinical outcomes is needed to establish concurrency and clinical significance.
SN - 1664-0640
ER -